Eli Lilly leads biotech M&A in H1, leveraging obesity drug success and trillion-dollar scale

Eli Lilly, already the largest pharmaceutical company, has emerged as a leading buyer of biotech assets in the first half of 2026.

Its trillion-dollar market size and recent successes in obesity treatments have driven a series of acquisitions that broaden its biotech portfolio.

Industry observers say the pace of deals shows no sign of slowing, positioning Lilly to deepen its pipeline beyond its traditional strengths.